Joseph Wendell Wilson

This inventor holds 7 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignees: Eli Lilly and Company, Glaxosmithkline LLC, Icagen, Inc.. Active years: 2000-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joseph Wendell Wilson. Retrieved from https://idiyas.com/inventor/joseph-wendell-wilson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 57.1

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 7.7

ph-index = 4

Forward Citations = 38(Granted Patents)

Company Filing History:

4 out of 4,514

Eli Lilly and Company

where one patent can have more than one assignee

Years Active: 2000-2011

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7981903 - 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer (2011-07-19),

2. 7812022 - 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors (2010-10-12),

3. 7807673 - 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors (2010-10-05),

4. 6429317 - Indane derivatives for antipsychotic compositions (2002-08-06),

5. 6395735 - Pharmaceutical compounds (2002-05-28),

6. 6221876 - Methods for inhibiting MRP1 (2001-04-24),

7. 6083986 - Potassium channel inhibitors (2000-07-04),

Title: Joseph Wendell Wilson: Innovator in Pharmaceutical Chemistry

Introduction

Joseph Wendell Wilson is a notable inventor based in Durham, NC (US). He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 7 patents. His work primarily focuses on developing innovative compounds for medical applications, particularly in cancer treatment.

Latest Patents

Among his latest patents, Wilson has developed compounds such as 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives, which serve as IGF-1R inhibitors for cancer treatment. These novel pyrrolopyrimidines are designed to inhibit IGF-1R effectively. Additionally, he has patented 2-pyrimidinyl pyrazolopyridine compounds, which are ErbB kinase inhibitors. These compounds and their compositions are intended for use as pharmaceutical agents, showcasing Wilson's commitment to advancing medical science.

Career Highlights

Throughout his career, Wilson has worked with prominent companies in the pharmaceutical industry, including Eli Lilly and Company and GlaxoSmithKline LLC. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research and development.

Collaborations

Wilson has collaborated with notable colleagues such as Sean Patrick Hollinshead and Philip Floyd Hughes. These partnerships have further enhanced his innovative capabilities and expanded the impact of his work in the field.

Conclusion

Joseph Wendell Wilson is a distinguished inventor whose contributions to pharmaceutical chemistry have the potential to transform cancer treatment. His innovative patents and collaborations reflect his dedication to advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.